CA
NZ
UK
AU
IND
US
Inotiv (NASDAQ: NOTVQ) saw its prepackaged Chapter 11 plan confirmed on July 14, 2026, sealing the fate of its existing equity. The court order mandates the cancellation of every outstanding common share, 35,172,908 in total, leaving current shareholders with no residual value. In exchange, …
Dyne Therapeutics has locked in $125 million in non-dilutive capital, a move that analysts say extends its runway while advancing treatments for rare neuromuscular diseases. The biotech’s shares, up 31.1% in the past month, edged 0.3% higher to $23.84 in recent trading, reflecting investor …
Veritas Association Management has secured a notable industry distinction, earning AMC Institute Accreditation and joining a limited number of firms globally that meet the organization’s rigorous criteria. The accreditation, granted July 15, 2026, reflects elevated operational and financial standards for association management, particularly in …
Aspira Women's Health (NASDAQ: AWHL) has finalized a $1,050,000 subordinated loan aimed at refinancing existing obligations and strengthening its operating liquidity. The transaction, documented in a Subordinated Business Loan and Security Agreement (referenced as EX‑10.1), incorporates $441,000 of accrued interest and provides the company …
Autonomix Medical (NASDAQ: AMIX) has secured a capital infusion of approximately $2.6 million by revising its warrant arrangement. This restructuring converts the earlier Series C warrants into common stock while extending the holder’s opportunity to acquire more equity under the new terms. The additional …
Cogent Biosciences (NASDAQ: COGT) is positioning bezuclastinib to become the first FDA‑approved therapy for patients with advanced systemic mastocytosis. The company’s New Drug Application, submitted on June 30, draws on encouraging data from its APEX trial and places the drug on a pathway toward …
AEON Biopharma has completed a $12.2 million public offering, providing the company with critical capital to advance its biosimilar development program. The offering arrives as AEON Biopharma works to secure its financial position while progressing ABP-450, its biosimilar candidate designed to compete in the …
Three small-cap biotechs reported significant corporate developments in the same period that collectively illustrate the diverse capital allocation strategies available to life sciences companies at different stages of commercial and financial development: Arbutus Biopharma (NASDAQ: ABUS) returning capital from IP monetization, Virax Biolabs (NASDAQ: …
The safety data itself was genuinely encouraging on its own terms. All side effects observed during the initial dosing cycles were fully manageable with standard supportive care, resulting in zero treatment-related serious adverse events or Grade 3 or higher toxicities. For a combination therapy …
Eli Lilly and Company (NYSE: LLY) announced a definitive agreement on July 16, 2026, to acquire AtaiBeckley Inc. (NASDAQ: ATAI) in a transaction valued at up to approximately $3.8 billion, marking one of the most significant moves by a large-cap pharmaceutical company into the …
Please wait processing your request...